Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11961359 | 1.00 | CA2 (0.36) | CA2CA1CA9 | |
| SCHEMBL11981760 | 1.00 | CA2 (0.36) | CA2CA1CA9 | |
| SCHEMBL11961356 | 1.00 | CA2 (0.36) | CA2CA1CA9 | |
| SCHEMBL5839806 | 1.00 | CA2 (0.36) | CA2CA1CA9 | |
| SCHEMBL345905 | 1.00 | CA2 (0.36) | CA2CA1CA9 | |
| SCHEMBL12060575 | 0.92 | CA2 (0.39) | CA2CA1CA9 | |
| SCHEMBL20367420 | 0.83 | CA1 (0.31) | CA2CA1CA9 | |
| SCHEMBL15678414 | 0.81 | CA2 (0.45) | CA2CA1CA9 | |
| SCHEMBL29525029 | 0.81 | CA1 (0.31) | CA2CA1CA9 | |
| SCHEMBL13592460 | 0.80 | CA2 (0.44) | CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3255043-B1 | N-(6-((2R,3S)-3,4-DIHYDROXYBUTAN-2-YLOXY)-2-(4-FLUOROBENZYLTHIO)PYRIMIDIN-4-YL)-3- METHYLAZETIDINE-1-SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2021-01-20 | — | — | EP | disclosed |
| EP-3255043-B1 | N-(6-((2R,3S)-3,4-DIHYDROXYBUTAN-2-YLOXY)-2-(4-FLUOROBENZYLTHIO)PYRIMIDIN-4-YL)-3- METHYLAZETIDINE-1-SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2021-01-20 | — | — | EP | disclosed |
| US-9975881-B2 | Compound | ASTRAZENECA AB (SE) | 2018-05-22 | — | — | US | disclosed |
| US-9975881-B2 | Compound | ASTRAZENECA AB (SE) | 2018-05-22 | — | — | US | disclosed |
| US-9975881-B2 | Compound | ASTRAZENECA AB (SE) | 2018-05-22 | — | — | US | disclosed |
| EP-3141235-A1 | N-(6-((2R,3S)-3,4-DIHYDROXYBUTAN-2-YLOXY)-2-(4-FLUOROBENZYLTHIO)PYRIMIDIN-4-YL)-3-METHYLAZETIDINE-L -SULFONAMIDE | IP Gesellschaft für Management mbH (DE) | 2017-03-15 | — | — | EP | disclosed |
| EP-2740458-B1 | Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide | IP GES FÜR MAN MBH (DE) | 2016-08-03 | — | — | EP | disclosed |
| US-20160108023-A1 | Novel Compound | ASTRAZENECA AB (SE) | 2016-04-21 | — | — | US | disclosed |
| US-20160108023-A1 | Novel Compound | ASTRAZENECA AB (SE) | 2016-04-21 | — | — | US | disclosed |
| US-20160108023-A1 | Novel Compound | ASTRAZENECA AB (SE) | 2016-04-21 | — | — | US | disclosed |
| US-20130040926-A1 | NOVEL COMPOUND | ASTRAZENECA UK LIMITED | 2013-02-14 | — | — | US | disclosed |
| US-20130040926-A1 | NOVEL COMPOUND | ASTRAZENECA UK LIMITED | 2013-02-14 | — | — | US | disclosed |
| US-20130040926-A1 | NOVEL COMPOUND | ASTRAZENECA UK LIMITED | 2013-02-14 | — | — | US | disclosed |
| WO-2013008002-A1 | N- (6- ( (2R,3S) -3,4-DIHYDROXYBUTAN-2-YLOXY) -2- (4 - FLUOROBENZYLTHIO) PYRIMIDIN- 4 - YL) -3- METHYLAZETIDINE- 1 - SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2013-01-17 | — | — | WO | disclosed |
| US-20120202287-A1 | Stem Cell Culture Methods | ITI SCOTLAND LIMITED (GB) | 2012-08-09 | — | — | US | disclosed |
| US-20120015927-A1 | CRYSTALLINE FORMS OF N-[2-[[(2,3-DIFLUOROPHENYL)METHYL]THIO]-6--4-PYRIMIDINYL]-1-AZETIDINESULFONAMIDE | ASTRAZENECA AB (SE) | 2012-01-19 | — | — | US | disclosed |
| WO-2012007748-A1 | NEW CRYSTALLINE FORMS OF N-[2-[[(2,3-DIFLUOROPHENY)METHYL)THIO]-6-{[(1R,2S)-2,3-DIHYDROXY-1- METHYLPROPYL]OXY}-4-PYRIMIDINYL]-1-AZETIDINESULFONAMIDE | ASTRAZENECA AB (SE) | 2012-01-19 | — | — | WO | disclosed |
| US-7049447-B2 | Aziridine derivatives and their preparation methods | SAMCHULLY PHARM. CO.,LTD. (KR) | 2006-05-23 | — | — | US | disclosed |
| US-20040097480-A1 | Aziridine derivatives and their preparation methods | SAMCHULLY PHARM. CO., LTD. (KR) | 2004-05-20 | — | — | US | disclosed |
| WO-2001072698-A1 | OPTICALLY ACTIVE CYANOBUTANTRIOL DERIVATIVES AND PROCESS FOR PREPARING SAME | KUKJE PHARMA. IND. CO., LTD. (KR) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040926-A1 | NOVEL COMPOUND | CXCR2, CXCR1, CCR5 | CA2 2395/4885CA1 3867/4885CA9 2447/4885 |
| US-20160108023-A1 | Novel Compound | CXCR2, CXCR1, CCR5 | CA2 2395/4885CA1 3867/4885CA9 2447/4885 |
| US-20120015927-A1 | CRYSTALLINE FORMS OF N-[2-[[(2,3-DIFLUOROPHENYL)METHYL]THIO]-6--4-PYRIMIDINYL]-1-AZETIDINESULFONAMIDE | CXCR1, CXCR2, CCR2 | CA2 207/4885CA1 330/4885CA9 138/4885 |
| US-20120202287-A1 | Stem Cell Culture Methods | KIT, SOX18, MCL1 | CA2 1970/4885CA1 345/4885CA9 1745/4885 |
| US-20040097480-A1 | Aziridine derivatives and their preparation methods | AZI2, AAAS, HRH2 | CA2 2228/4885CA1 3761/4885CA9 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.